Consumer: Retailing/Food & Drug Chains
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Consumer: Retailing/Food & Drug Chains

Dubbed by one fund manager “the dean of the supermarket and drug retail space.

100x102-adlermeredith.jpg
Meredith Adler Barclays


second team Edward Kelly Credit Suisse


third team Deborah Weinswig Citi


Dubbed by one fund manager “the dean of the supermarket and drug retail space,” Meredith Adler of Barclays Capital seizes the top spot for an eighth consecutive year. Adler, 55, was on the ­money when she upgraded Dollar Tree from hold to buy in November 2007, at $26.21, on the Chesapeake, ­Virginia–based discount store chain’s growing market share. The stock soared to $43.25 — a gain of 65 percent that far outdistanced the sector’s 14.2 percent drop — in April 2009, and she downgraded it to hold. Adler told investors the com­pany’s strong performance ­didn’t appear sustainable in a weakening economy, but her downgrade appears to have been premature: The shares advanced 15.5 percent further, to $49.94, through August.


Newcomer Edward Kelly shoots straight to second place. The ­Credit ­Suisse analyst is praised by supporters for being “appropriately skeptical about his companies” and “ahead of the curve” on Walgreen Co. Kelly upgraded the Deerfield, Illinois–based ­drugstore chain from neutral to outperform in July 2008, on improving profitability. Through August 2009 the stock was ahead of the sector by 15 percentage points.


Repeat third-­teamer ­Deborah Weinswig is “one of the best communicators on the Street,” insists one buy-side ­backer. The ­Citi analyst, who also is No. 1 in Retailing/Broadlines & Department Stores, advised clients to sell Kroger Co. in February, at $22.91, on the belief that the Cincinnati-­based supermarket operator would suffer in a “modern-­day price war” with competitors. Within a month the stock had fallen 15.1 percent, to $19.46, but by August 31 it had recovered to $21.59.


Click here to see the All-America Research Team rankings.


Related

In changing times, Mislav Matejka and his equity strategy team at J.P. Morgan are big vote-getters on the 2017 All-Europe Research Team.
BTG Pactual lands in second place for a second consecutive year.
Nine firms have analysts appearing on the team for the first time.
Gift this article